)
Bayer (BAYN) investor relations material
Bayer Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 sales rose 4.1% reported to €10.053bn and 1.9% currency- and portfolio-adjusted; EBITDA before special items increased 6.9% to €1.615bn.
Pharmaceuticals drove growth, while Crop Science and Consumer Health faced pressure; full-year guidance rose for EBITDA, free cash flow, net financial debt and Pharma margin.
Financial highlights
Q3 net income was -€672m and core EPS fell 36.7% to €0.31; free cash flow was -€293m, including €1.121bn of net legal-proceeding outflows.
Nine-month sales were €34.330bn, up 2.9% currency- and portfolio-adjusted; EBITDA before special items rose 6.6% to €8.212bn and core EPS was €3.97.
Nine-month free cash flow was -€3.0bn, including €3.7bn of litigation payouts; net financial debt declined to €31.083bn, supported by the €3.0bn Apollo contribution.
Outlook and guidance
FY2026 currency-adjusted EBITDA before special items guidance rose to €9.8–10.3bn from €9.6–10.1bn; core EPS guidance remained €4.30–4.80.
Free cash flow guidance improved to -€1.5bn to -€0.5bn, including €5bn of litigation payouts; year-end net financial debt guidance fell to €28–29bn.
Pharma margin guidance increased to 25–27% from 23–25%, with sales growth expected toward the upper end of its 0–3% range; Crop Science and Consumer Health market outlooks were lowered.
- FY22 earnings surged, led by Crop Science; inflation and price pressure cloud FY23.BAYN
Q4 2022 - Turnaround targets pair innovation-led growth with operational savings and debt reduction.BAYN
Corporate presentation - Pharma-led Q3 growth lifted results and improved 2026 guidance.BAYN
Q3 2026 (Media) - Above-market growth, margin expansion, and innovation are on track, driven by blockbuster launches.BAYN
Investor update - Strong 2025 results, innovation focus, and €2bn cost savings drive improved financial outlook.BAYN
Corporate presentation - Sales up 3%, Crop Science drives earnings, Apollo investment lowers net debt outlook.BAYN
Q2 2026 (Media) - Q2 2026 saw sales and earnings growth, positive net income, and reaffirmed guidance with lower debt.BAYN
Q2 2026 - New launches and pipeline advances drive growth despite Xarelto and Crop Science headwinds.BAYN
43rd Annual J.P. Morgan Healthcare Conference 2025 - Pharma and Consumer Health growth offset Crop Science decline; 2025 outlook steady amid legal, FX risks.BAYN
Q1 2025
)
)
)
)
)
)
)
)